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Background: We examined the impact of urologist academic affiliation on use of androgen deprivation therapy
(ADT) for prostate cancer before and after major reimbursement cuts for ADT in hopes of better understanding
the influence of financial incentives on its use. In particular, we hypothesized that if financial incentive was the
predominant factor driving use, we should see a narrowing in the previously documented gap of ADT use between
non-academic and academic urologists following the reimbursement cuts.
Methods: With the Surveillance, Epidemiology and End-Results (SEER)-Medicare linked database we examined use
of ADT for potentially inappropriate indications (primary therapy of localized, lower risk tumors) among patients of
2214 urologists over the period 2000–2002 and 2004–2007, representing eras before and after reimbursement cuts.
Multi-level logistic regression models were used to estimate the likelihood of ADT use adjusted for patient, tumor
and urologist characteristics (academic affiliation, board certification, years in practice and patient panel size).
Results: Overall, ADT use peaked in 2002 at 46.6% of patients, but dropped dramatically in 2005, with a slow
continued decrease through 2007 to 31.1%. A similar pattern was evident within most strata of urologist
characteristics, including academic affiliation. In the multilevel model, patients of non-academic urologists had
a 30% higher odds of receiving ADT than those of academic urologists in both the eras before and after the
reimbursement cuts.
Conclusion: A similar proportionate drop in use of ADT among both academic and non-academic urologists
following reimbursement cuts suggests that factors other than financial incentives may have played a role.
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Androgen deprivation therapy (ADT), either in the form
of gonadotropin-releasing hormone (GnRH) agonists or
orchiectomy, has long been used for palliation of meta-
static prostate cancer [1,2]. Starting in the 1990s, there
was an explosive growth in use of ADT with a broaden-
ing of its application to earlier stages of disease [3]. Al-
though this was driven in part by clinical trial evidence
of benefit in some settings, such as adjuvant ADT to-
gether with radiation therapy for high-risk prostate
cancer [4], there have been concerns about possible* Correspondence: vahakn@umich.edu
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unless otherwise stated.financial motivations for its use. Medicare reimburse-
ment policies made administration of GnRH agonists
very profitable (due to large discounts in the acquisition
price of the drugs by physicians as compared to
reimbursement) [5], and we have previously shown that
patients of non-academic urologists (who are more usu-
ally paid fee-for-service) were 60% more likely to receive
ADT in settings of uncertain benefit than patients of
academic urologists (who are more likely salaried) [6].
More recently in 2005, Medicare reimbursement policy
changes related to the Medicare Modernization Act in
2003 cut payment for GnRH agonists by over 50%,
which was followed by substantial reductions in use
of ADT [7]. Although these findings suggested that
financial incentives played an important role, otherentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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same period, there was growing recognition of poten-
tially serious adverse effects related to ADT [8-10]. We
therefore examined the impact of urologist characteris-
tics on use of ADT over the period of the reimburse-
ment cuts, with the objective of further clarifying the
factors driving the reductions in its use. In particular, we
hypothesized that if financial incentive was the sole, or
predominant, factor, we should see a narrowing in the
gap of ADT use between academic and non-academic
urologists following the reimbursement cuts.
Methods
The study protocol was approved by the local institu-
tional review board at the University of Michigan.
Data sources
Surveillance, Epidemiology, and End Results (SEER)-Medicare
The SEER program consists of a group of population-
based tumor registries in selected geographic areas of
the US [11]. It covered 14% of the US population until
2001, and 26% thereafter. Medicare is a federal program
that covers health services for 97% of persons aged
65 years and older. The information in the two programs
has been linked. The SEER-Medicare database also con-
tains the Hospital file, which includes information on
hospital characteristics such as academic affiliation and
is derived from the Provider of Service survey submit-
ted by hospitals to Medicare. The SEER-Medicare
database version used for this study contains Medicare
claims through 2008 and cancer cases from SEER
through 2007.
American Medical Association (AMA) Physician Masterfile
The AMA Physician Masterfile collects information on
all physicians in the US, regardless of membership in the
AMA [12]. The information is collected from primary
sources, such as medical schools, residency training pro-
grams, state licensing agencies, and the American Board
of Medical Specialties. Physicians are also surveyed every
3 years regarding their current practice.
Study subjects
Men with incident prostate cancer from 2000 through
2002, and from 2004 through 2007, (men diagnosed in
the year 2003 were excluded for reasons described below
in the Study Variables section) who were at least 66 years
old at diagnosis (n = 191,990) were initially selected. To
ensure complete information, patients not enrolled in
both Medicare Part A and Part B for 12 months before
and 6 months following their cancer diagnosis (n = 19160),
who died within 6 months of diagnosis (n = 3527),
were members of an Health Maintenance Organization
(n = 47833), or diagnosed by autopsy or on a deathcertificate (n = 2388) were excluded. The main interest
for this study was the examination of ADT use for poten-
tially inappropriate indications given the large changes in
such use noted after the reimbursement cuts [7] and
known variations in rates of such use as a function of ur-
ologist characteristics [6]. We previously defined this
group as men diagnosed with clinically localized (T1
or T2), low to moderate grade (Gleason 2 to 7) tumors,
who did not receive treatment with radiation or radical
prostatectomy. Use of ADT in that context would be po-
tentially inappropriate given there is no clinical trial evi-
dence supporting its efficacy as primary therapy [13], and
even under theoretical considerations, it is difficult to
show survival benefit from any intervention in such pa-
tients, due to the slow natural progression and competing
risk of death from causes other than prostate cancer [14].
This led to the exclusion of an additional n = 91913 pa-
tients (in whom ADT use would have been categorized
as either discretionary or appropriate), leaving n = 27169
eligible patients for the main analysis.
Physicians providing care to patients within a year of
diagnosis were initially identified through encrypted
Unique Physician Identifier Numbers (UPINs) on
Medicare physician claims, as previously published [15].
Briefly, UPINs were linked to the AMA Physician
Masterfile and only physicians with urology as their pri-
mary specialty code were selected. Patients who did not
see at least one urologist in the year after diagnosis on at
least two different days were excluded. If a patient saw 2
or more urologists, they were assigned to the urologist
with ≥75% of urologist visits in the year after diagnosis. If
no single urologist accounted for ≥75% of the visits, the
patient was excluded.
Study variables
Patient demographic and tumor characteristics were de-
rived from the SEER records in the linked database and
used to categorize patients by age, ethnicity, SEER region
of residence at the time of diagnosis, year of diagnosis,
clinical stage (T1 through T4), and grade (low - Gleason
2–4; moderate - Gleason 5–7; poor - Gleason 8–10).
Stage was assigned using the SEER Extent of Disease-
Clinical Extension classification system prior to 2004
and using the Collaborative Stage Clinical Extension
system from 2004 onwards [7]. Cancer grade was cate-
gorized only as a range as low (Gleason 2–4), moderate
(Gleason 5–7) or high (Gleason 8–10) prior to 2003, but
in 2003 only Gleason 7 was switched to the high grade
category. From 2004 onwards, individual Gleason scor-
ing has been available, allowing classification into similar
groupings as for the data prior to 2003. To ensure com-
parability across the study period men with incident
prostate cancer in 2003 were therefore excluded. The
socio-economic characteristics of each patient were based
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cation and median income of the zip code of residence
from the 2000 United States Census data. Comorbidity
was measured using an adaptation of the Charlson
Comorbidity Index for use with Medicare physician
claims data, based on the period one year prior to diag-
nosis of prostate cancer [16,17].
Urologist board certification was available from the
AMA based on information from the American Board
of Medical Specialties [12]. Patient panel size was de-
fined as the number of patients with incident prostate
cancer (regardless of ADT use) assigned to each urolo-
gist over the entire study period, and categorized as <14,
14–44, 45–74, and ≥75 patients. The categorization used
was similar to an approach we utilized in a previous
publication, chosen to ensure a reasonable distribution
for the number of patients, with cut-offs roughly corre-
sponding to the 2nd quartile, 3rd quartile and 90th per-
centile [6]. Hospital academic affiliation was available
from the SEER-Medicare Hospital file. Hospitals with a
major academic affiliation were those that played an im-
portant role in the teaching program of a medical
school. Hospitals with a minor academic affiliation had
academic involvement limited to hosting of a residency
program or occasional medical student rotations [6].
Urologists were categorized as having an academic affili-
ation if all their inpatient Medicare claims submitted
were from a hospital with major or minor academic af-
filiation. These urologists would be more likely to be sal-
aried, through employment with a medical school, or
hospital. All other urologists were categorized as having
no academic affiliation. These urologists would be more
likely to be in private practice or part of single specialty
groups, and therefore derive most of their income from
fee-for-service activities. In initial analyses of academic
affiliation using three categories (major, minor or none)
patterns of ADT use were essentially identical between
urologists with major and minor academic affiliation.
Therefore, to optimize statistical power the main ana-
lyses were presented using a binary classification: major
or minor academic affiliation vs. none.
The outcome was receipt of androgen deprivation.
Androgen deprivation was defined as the receipt of
at least one dose of a GnRH agonist (identified through
Medicare claims codes used to designate each dose given
of injectable medications [8]) or orchiectomy (defined by
the presence of the Current Procedural Terminology codes
or International Classification of Diseases, 9th revision
[ICD-9] procedure codes in the Medicare claims) in the
first six months following diagnosis of cancer.
Statistical analyses
Differences across strata of urologist characteristics in
the proportion of patients receiving ADT were tabulated.The effect of urologist characteristics on the outcome of
use of androgen deprivation was evaluated using multi-
level logistic regression models to account for clustering
of patients within urologists. Models entering the urolo-
gist, patient and tumor characteristics listed above as in-
dependent variables were estimated. Odds ratios (OR)
for the use of androgen deprivation for each urologist
characteristic were calculated along with 95% confidence
intervals (CI). As the main interest was to examine how
the effect of urologist characteristics changed related to
reimbursement cuts, the model results were stratified
into two eras, 2000–2002 (prior to the reimbursement
cut) and 2004–2007 (following the reimbursement cut).
To specifically assess whether there were significant
changes in the effect of urologist characteristics on use
of ADT over the course of the two eras, tests of inter-
action were performed between each urologist character-
istic and era, on the outcome of ADT use. In addition,
the median urologist rates of androgen deprivation use
as a function of academic affiliation were estimated from
the models, and plotted by calendar year of diagnosis to
show change in use over time. Analyses were performed
with SAS version 9.3 (Cary, NC). All tests of statistical
significance were two sided, with P values of less
than .05 being considered significant.
Results
A total of 2,214 urologists were identified as providing
care to patients with incident prostate cancer over the
study period. A majority of urologists were board certi-
fied (77.9%), had either a major or minor academic affili-
ation (66.2%), and were male (97.5%). Trends over time
in the proportion of patients receiving ADT for inappro-
priate indications are presented in Table 1, stratified by
urologist characteristics. In the overall cohort, such use
peaked in 2002 at 46.6% of patients, but dropped dra-
matically in 2005, with a slow continued decrease
through 2007 to 31.1%. A similar pattern was evident
within most strata of urologist characteristics. Patients
of older urologists, those practicing longer, and those
without an academic affiliation tended to have higher
rates of ADT use.
Table 2 presents multilevel models showing the odds
of ADT use for inappropriate indications as a function
of urologist characteristics, stratified by era of use
(2000–2002 vs. 2004–2007). The only significant finding
was an increase in the odds of ADT use for patients of
non-academically affiliated urologists (vs. urologists with
either a major or minor academic affiliation), which was
similar in both eras. None of the tests for interaction be-
tween era and urologist characteristics on the outcome
of ADT use were significant.
The Figure 1 shows a plot of median urologist rates of
ADT use for inappropriate indications over time for
Table 1 Proportion of patients receiving androgen deprivation therapy for inappropriate indications by year, stratified
by urologist characteristics
Urologist characteristics Categories Urologist sample ADT use for inappropriate indications by year
N % 2000 2001 2002 2004 2005 2006 2007
Total 2214 100 44.2 44.3 46.6 44.7 36.2 33.4 31.1
Age (years): <45 694 31.3 40.9 45.4 48.2 40.4 33.5 30.2 29.6
45 - 54 630 28.5 44.2 44.1 44.4 46.0 37.8 32.4 30.2
55 - 64 672 30.4 45.2 42.4 46.1 45.7 35.4 35.0 32.5
≥65 218 9.8 48.7 49.2 55.1 45.6 38.9 41.7 35.5
Sex: Female 55 2.5 38.5 44.4 26.9 31.8 33.3 34.4 34.5
Male 2159 97.5 44.3 44.3 46.7 44.8 36.2 33.4 31.1
Years in practice: <15 864 40.1 39.7 43.2 46.1 41.7 33.5 30.8 28.4
15 - 24 548 25.4 43.5 42.6 44.0 46.3 39.9 32.9 33.2
25 - 34 488 22.6 47.6 44.5 47.9 44.4 33.5 35.4 31.3
≥35 255 11.8 48.1 47.1 53.0 46.4 40.7 40.7 34.0
Board certification: Yes 1725 77.9 44.6 44.1 46.0 44.2 36.1 33.5 30.9
No 489 22.1 42.7 44.9 48.8 46.4 36.8 33.0 31.9
Academic affiliation: Major or Minor 1338 66.2 41.5 43.2 44.7 41.9 33.3 31.9 28.9
None 684 33.8 47.6 46.0 49.0 48.2 40.1 35.5 33.6
Patient panel size (no. of patients): <14 685 30.9 37.7 44.7 42.1 46.1 34.7 35.6 29.2
14 - 44 603 27.2 39.8 40.6 47.3 43.1 36.7 32.0 30.1
45 - 74 452 20.4 47.2 48.2 47.2 44.9 37.8 33.4 36.0
≥75 474 21.4 47.6 43.7 49.3 44.6 35.6 32.9 29.0
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demic affiliation versus urologists without an academic
affiliation. Among both groups, there was a drop in use
starting in 2004, but the gap between them remained
relatively constant throughout the study period.Table 2 Odds of ADT use in multilevel models as a function o
Urologist characteristics ADT use by era
a2000-2002
Odds ratio 95% CI
Years in practice (per 5 years) 1.01 (0.97, 1.05)
Board certification
Yes ref
No 1.01 (0.82, 1.24)
Academic affiliation
Major or minor ref
None 1.32 (1.17, 1.56)
Patient panel size
<14 ref
14 - 44 1.02 (0.84, 1.25)
45 - 74 1.23 (0.99, 1.54)
≥75 1.10 (0.86, 1.40)
aBased on multilevel model with patient age, comorbidity, ethnicity, SEER region, tu
poverty entered as “level 1” variables and urologist characteristics entered as “level
sample size. Urologist age was not entered into the models due to collinearity withDiscussion
This study shows a drop in use of ADT for inappropriate
indications following reimbursement cuts for GnRH
agonists in 2004 and 2005, which occurred among pa-
tients of both academic and non-academic urologists.f urologist characteristics, stratified by era
a2004-2007
Odds ratio 95% CI p-value interaction with era
1.03 (1.00 ,1.07) 0.47
ref
1.06 (0.89, 1.28) 0.94
ref





mor stage, grade, year of diagnosis, census tract education, and census tract
2” variables. Urologist sex was not entered into the models due to low female
the years in practice variable.
Figure 1 Median urologist rate of androgen deprivation (ADT) for inappropriate indications, based on the multilevel model from Table 2, by
calendar year of diagnosis and stratified by urologists with academic (major or minor) versus no academic affiliation.
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among non-academic urologists, the gap between
them and academic urologists remained constant from
the period before through the period after the reim-
bursement cuts.
We initially argued that if the reductions in use of
ADT were purely financially motivated, we would expect
to see a narrowing in the gap between academic and
non-academic urologists as the latter would be most af-
fected in a direct manner by cuts in reimbursement for
GnRH agonists. Our findings were not consistent with
such a pattern, suggesting that factors other than finan-
cial incentives may have also played a role. In support of
this, previous work done in other health care contexts in
which financial incentives were absent has also demon-
strated a decrease in use of ADT over a similar period
[18,19]. A Canadian study examining the Ontario
province-wide database showed a slow but steady de-
cline in the rate of new ADT initiation starting in the
late 1990s and continuing through 2005 [19]. Most of
that reduction was for use of ADT as a primary therapy.
In a US study utilizing data from the Veterans Health
Administration, pharmacy claims for use of GnRH ago-
nists declined 16.8% from 2004 to 2007 [18]. However,
the data presented was limited to counts, without exam-
ination of rates, or indications for use. The main com-
peting explanation for the recent reductions in use of
ADT is the concern for adverse effects. Recognition of
the impact of ADT on quality of life, anemia and osteo-
porosis was evident as early as the 1990s [20-23]. How-
ever, it was not until 2005 and later that a series of highimpact publications demonstrated potentially life threat-
ening consequences such as fractures, cardiovascular
disease and diabetes mellitus, which may have strongly
discouraged use of ADT in settings without clear evi-
dence of benefit [8-10]. Ultimately it is likely that a
number of factors in combination led to the observed
findings in our study, with contributions from both con-
cerns over adverse effects as well as reduced financial
incentives.
The persistent gap in use as a function of academic
affiliation even after much of the financial incentive was
removed may relate to differences in the interactions be-
tween urologists and patients. The pressure to provide
some sort of treatment in the face of a cancer diagnosis
may be a strong factor in the decision to use ADT in
place of watchful waiting for patients with localized
prostate cancer who are otherwise not good candidates
for radiation treatment or radical prostatectomy. Physi-
cians in academic settings may have more time for dis-
cussion of risks and benefits, leading patients to choose
more conservative courses of action [24]. However, no
studies have directly examined whether discussion be-
tween patients and urologists about ADT differ between
academic versus non-academic urologists.
There are limitations to this study. Only men 66 years
and older were included, and use of androgen
deprivation in health maintenance organizations could
not be examined. Assignment of urologist academic af-
filiation, based on Medicare claims, may have been im-
perfect. However, misclassification would tend to bias
the results to the null, so that significant associations
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actions between era and the effect of urologist character-
istics on ADT use may have been limited. Nevertheless,
inspection of the point estimates reveals no obvious dif-
ferences in effect between the two eras, making it less
likely that an interaction was missed due to insufficient
sample size. Finally, due to limitations in the granularity
of clinical detail available in a claims-based analysis, not
all ADT use deemed inappropriate by our study defin-
ition is necessarily unreasonable. However, our main
intention was to examine differences in ADT use be-
tween academic and non-academic urologists, which we
felt (and had previously demonstrated) would be most
prominent in settings where evidence of efficacy was
most lacking.
Conclusion
In conclusion, although the study findings do not rule
out a role of financial incentive in the observed patterns
of ADT use, they suggest that the explanation is likely to
be more complex.
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